$TEM

Epstein David R sold $16K of TEM

Epstein David R sold 370 shares of Tempus AI, Inc. (TEM) at $43.40 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Epstein David R
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director under a pre-arranged 10b5-1 plan, which typically reduces interpretive value for near-term fundamentals.

02

Market read

Traders may log the transaction for insider-flow monitoring, but it is unlikely to drive a standalone repricing.

03

What to watch

The article does not state whether other insiders sold/bought, nor does it provide total insider ownership changes beyond the post-transaction share count.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-05 for a sale dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Tempus AI, Inc.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI director David R Epstein sold 370 shares at $43.40 under a pre-arranged 10b5-1 plan, totaling $16,058.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed sale size is modest relative to typical market moves.

Market effects

No clear sector read-through from a single, small 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with private information, so traders may still watch for follow-on filings or changes in insider activity.

Key entities

  • Tempus AI, Inc.

    Company whose director insider sale is disclosed on Form 4.

  • David R Epstein

    Director who sold 370 shares at $43.40 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.